Abstract:Objective: To observe the efficacy and safety of combined thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) and urokinase (UK) on patients with acute cerebral infarction. Method: Eighty-one patients with acute cerebral infarction (< 6 hours from onset) were recruited and randomly allocated into four groups: combined thrombolysis group (n = 20), rt-PA group (n = 22), UK group (n=18), and control group (n = 21). The patients in combined thrombolysis group received rt-PA 20 mg and UK 300 000 - 500 000 IU; the patients in rt-PA group received rt-PA 0.9 mg/kg intravenously; the patients in UK group received UK 10 000 - 20 000 IU/kg (patients with body weight > 75 kg received the same dose of medication as 75 kg), and the maximum dose of UK was 1 500 000 IU; the patients in the control group received to no thrombolytic drugs. The outcome score were evaluated according to the National Institute of Health Stroke Scale (NIHSS) before treatment and four weeks after symptom onset, and to evaluate hemorrhagic transformation, recurrent infarction, and death as the safety indicators. Results: 1Before treatment the NIHSS scores in the combined thrombolysis, rt-PA, UK, and control groups were 18.1 ± 3.6, 17.9 ± 3.6, 18.0 ± 3.4, and 17.3 ± 4.0, respectively, and after treatment they were 9.1 ± 5.6, 8.8 ± 5.5, 9.6 ± 5.2, and 14.1 ±4.6, respectively. There were significant differences in each group before and after treatment (P <0.01), and also between the 3 thrombolysis groups and the control group (P < 0.01); but there were no significant differences between each other of the 3 thrombolysis groups. 2The total effective rates in the 4 groups but were 85.0% (17/20), 86.4% (19/22), 83.3% (15/18), and 42.9% (9/21), respectively. As compared between the 3 thrombolysis groups with the control group, there were significant differences (P < 0.05); and there were no significant differences among the 3 thrombolysis groups (P >0. 05). 3One patient had new attack of cerebral infarction, and 1 patient had hemorrhagic transformation within 24 hours after thrombolytic therapy in the combined thrombolytic group; 3 patients had hemorrhagic transformation in the rt-PA group; 1 patient had new attack of cerebral infarction in the UK group; 2 patients had hemorrhagic transformation, and 1 of them died. One patient had new attack of cerebral infarction, and 1 patient was died in the control group. Conclusion: The combined thrombolytic therapy with low-dose rt-PA and UK for the treatment of acute cerebral infarction is safe and effective.

Investigation of intravenous thrombolytic therapy with urokinase in 389 cases of unstable angina pectoris

A clinical study of high-dose urokinase for the treatment of the patients with hypertension induced ventricular hemorrhage

Thrombolysis Therapy by Intravenous Administering of Urokinase in 128 Patients with Acute Myocardial Infarction at Elementary Hospital

Urokinase Combined with Liposomal Alprostadil in the Treatment of Acute Myocardial Infarction

Evaluation of the efficacy and safety of recombinant prourokinase in patients with acute myocardial infarction

Treatment with Low-dose Urokinase for Unstable Angina:A Systematic Review

Study on the changes in the left ventricular diastolic function of the patients with acute myocardial infarction treated with the urokinase thrombolysis therapy within 3 hours or after 3 hours of attack

Urokinase Thrombolytic Therapy in Acute Myocardial Infarction

Studing of the Special Problems in Thrombolysis Cure of Acute Myocardial Infarction

Combined thrombolytic therapy with low-dose recombinant tissue plasminogen activator and urokinase for patients with acute cerebral infarction

Intravenous Thrombolysis with R-Tpa and UK for Treating Acute Cerebral Infarction

Comparative Study of Alteplase and Urokinase in Treatment of Acute ST-segment Elevation Myocardial Infarction in Basic Level Hospitals

Intravenous thrombolysis with urokinase for acute cerebral infarctions(within 6h from symptom onset)

Clinical Study On The Thrombolytic Effect With Different Doses Of Urokinase In Acute Myocardial Infarction

Clinical Observation on Deep Venous Thrombosis of Lower Extremity Treated with Urokinase

Low-dose tissue plasminogen activator is as effective as standard tissue plasminogen activator administration for the treatment of acute ischemic stroke.

Effect of Small Dose of Heparin Calcium for Unstable Angina

Analysis of the Clinical Effect of Thrombolysis Therapies in Patients with Acute Myocardial Infarction on Emergency

Changes of Vasoactive Substances Originated Endothelium on Patients with Unstable Angina Pectoris Treated by Low Dose of Urokinase

Comparative study on the efficacy and safety of alteplase and urokinase in the treatment of acute cerebral infarction.

Safety and Efficiency of Delayed Thrombolysis with Urokinase in the Treatment of Low Extremity Deep Venous Thrombosis